Parkinson disease (PD) affects an estimated 1 million patients in the United States and is a cause of significant disability for those affected.
1 For patients with advanced PD who have severe levodopa-induced motor fluctuations and dyskinesia, deep brain stimulation (DBS) has been found to be an effective treatment in reducing motor disability and improving quality of life.
2 As with any surgical procedure, DBS has inherent risks and has been associated with postoperative complications, including hemorrhage, wound infection, and pneumonia.
3 Recent results from the Controlled Trial of Deep Brain Stimulation in Early Patients with Parkinson’s Disease
4 (mean age, 52 years) demonstrated that DBS plus best medical therapy was superior to best medical therapy alone for patients with PD and early motor complications, potentially expanding the therapeutic window to treat patients earlier in the disease process. However, PD remains a chronic progressive disease of elderly populations, with a mean age at diagnosis of approximately 60 years and a disease duration of 14 years before DBS is performed.
5,6 The effect of increasing age on DBS candidacy and surgical complications is of increasing importance because the number of individuals with PD is expected to double by 2030.
7 The purpose of our study was to describe the population-level risk of adverse outcomes among older patients undergoing DBS for PD and to assess the effect of advancing chronologic age on postoperative complications. We hypothesize that increasing age would result in a higher number of postoperative complications, including risk of hemorrhage, wound infection, pneumonia, and pulmonary embolism in older patients with PD. Critical analyses are needed to provide much needed clinical evidence, influence future treatment strategies, and guide future health care policy.